ANNE-RENEE HARTMAN

M.D., Senior Vice President, Global Clinical Development, Myriad Genetics

Anne-Renee Hartman, M.D. is Vice President of Clinical Development at Myriad Genetic Laboratories. She is a medical oncologist with a strong background in molecular and clinical cancer genetics. Dr. Hartman joined the Company in 2007. In her current role, she is responsible for identifying, designing and executing retrospective and prospective clinical studies to demonstrate the clinical utility and validity of molecular diagnostics in the Myriad pipeline. She has overseen the clinical development of several diagnostic products including myPlan Lung, myPath Melanoma, myRisk and myChoice HRD. Before joining Myriad, Dr. Hartman was an Assistant Professor of Medicine at Harvard Medical School and the Dana Farber Cancer Institute, where she pursued translational research in the diagnosis and treatment of BRCA-associated cancers.

 

Integrated Genomic Platform for Companion Diagnostics

This talk will discuss the development and validation of Myriad’s homologous recombination deficiency (HRD) assay and the development of a second generation integrated genomic platform that combines HRD, high mutation load, and micro-satellite instability. These signatures can be used to identify tumors likely to respond to targeted therapies.

Web Analytics